FAES PHARMA is a Spanish pharmaceutical company with a global presence, dedicated to the research, development, manufacturing, and marketing of a diverse range of healthcare and nutrition products. Founded in 1933 and headquartered in Leioa, Spain, the company is listed on the Madrid, Barcelona, Bilbao, and Valencia stock exchanges.

FAES PHARMA operates through two primary business segments:

Pharma & Healthcare:
This division focuses on prescription medicines, over-the-counter (OTC) products, active pharmaceutical ingredients (APIs), food supplements, and personal care treatments. Key proprietary molecules include bilastine (an antihistamine), calcifediol (for Vitamin D deficiency), and mesalazine (for inflammatory bowel diseases). The company recently expanded its ophthalmology portfolio through the acquisitions of Portuguese and Italian specialists Edol and SIFI.

FARM Faes:
This segment specializes in animal nutrition and health products for livestock animals like pigs, ruminants, poultry, and aquaculture, operating through subsidiaries such as Ingaso Farm and Tecnovit.
Operations and Reach

Global Presence:
The company markets its products in over 130 countries across five continents, either through direct sales or licensing agreements. It has subsidiaries in numerous countries, including Portugal, Italy, Mexico, Guatemala, Colombia, Ecuador, Chile, Peru, and Nigeria.

R&D and Manufacturing:
FAES places a strong strategic focus on in-house research and innovation. It operates R&D and production facilities in Spain and other locations, with a new state-of-the-art manufacturing plant in Derio, Spain, completed in mid-2024 to significantly increase capacity.

Mission:
FAES is committed to developing and delivering innovative products to transform people’s health, striving for excellence and integrating sustainability into its business model.